An EUA for Bebtelovimab for Treatment of COVID-19
March 21, 2022 (Issue: 1646)
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at...more
- FDA News Release. Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant. February 11, 2022. Available at: https://bit.ly/3gMLn0L. Accessed March 3, 2022.
- An EUA for sotrovimab for treatment of COVID-19. Med Lett Drugs Ther 2021; 63:97.
- NIH. The COVID-19 Treatment Guidelines Panel’s statement on the role of bebtelovimab for the treatment of high-risk, nonhospitalized patients with mild to moderate COVID-19. March 2, 2022. Available at: https://bit.ly/35OhB9S. Accessed March 3, 2022.
- FDA. Fact sheet for health care providers. Emergency Use Authorization for bebtelovimab. February 11, 2022. Available at: https://bit.ly/3HO6goe. Accessed March 3, 2022.
- An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther 2021; 63:49.
- An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther 2020; 62:201.
- FDA Statement. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. January 24, 2022. Available at: https://bit.ly/3GVGsWR. Accessed March 3, 2022.
- HHS. Secretary Becerra announces HHS purchase of 600,000 treatment courses of new monoclonal antibody that works against Omicron. February 10, 2022. Available at: https://bit.ly/36lZoRf. Accessed March 3, 2022.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
